
Photo Credit: National Cancer Institute
Scientific Frontline: Extended "At a Glance" Summary: Hereditary CDK12 Mutation in Prostate Cancer
The Core Concept: Researchers have identified a rare, inherited mutation in the CDK12 gene that predisposes individuals to aggressive, metastatic prostate cancer at a relatively young age. This discovery expands the understanding of hereditary cancer risks beyond traditional markers like BRCA1 and BRCA2.
Key Distinction/Mechanism: Unlike previous assumptions that harmful CDK12 mutations arise only spontaneously within tumor cells, this study confirms they can be inherited; tumors associated with these mutations exhibit a distinct genetic signature indicating the gene has ceased to function correctly.
Major Frameworks/Components:
- Identification of germline (inherited) CDK12 mutations in five unrelated men with metastatic prostate cancer.
- Utilization of a distinctive genetic "fingerprint" left by non-functional CDK12 to confirm hereditary causality.
- Evidence suggesting potential cross-cancer risk, with findings indicating a possible link to an increased risk of ovarian cancer.
- Collaboration between UBC, BC Cancer, the Vancouver Coastal Health Research Institute, the University of Washington, and international partners.
.png)






.jpg)









.png)
